“…The development of our human plasma biofilm model (hpBIOM; Fig. 4a-c) (10,11), aims to narrow the gap between in-vitro and in-vivo biofilm research and provide a translational approach. The use of a complex biofilm model based on human material, including plasma and active immune cells, addresses the interactions of microbial biofilms with the human wound environment (3,14) as well as the relevant efficacy loss of antimicrobials under challenge (23,24), providing a 'close-to-reality' test scenario.…”